Inhibidores JAK y el riesgo de malignidades: Un Meta-análisis en las Indicaciones de la terapia
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.